<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884441</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-2010-002</org_study_id>
    <secondary_id>2010-022169-91</secondary_id>
    <nct_id>NCT01884441</nct_id>
  </id_info>
  <brief_title>Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients</brief_title>
  <official_title>Phase II Study With Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Before High Dose Chemotherapy With Autologous Hematopoietic Stem Cells Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armando Santoro, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Test of bendamustine in combination with gemcitabine and vinorelbine could contribute to a
      higher response rate with the reduction of toxic side effects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate bendamustine, gemcitabine and vinorelbine (BeGEV) scheme
      efficacy as induction therapy to high dose chemotherapy with Allogeneic Hematopoietic
      Stem-Cell Transplantation (AHSCT) for patients with relapsed/refractory Hodglin's Lymphoma
      (HL).

      Four BeGEV courses repeated every 3 weeks in the absence of any reasons listed in the
      paragraph 7.5; whenever an objective response is observed at disease evaluation performed
      after IV cycle patients undergo to high dose chemotherapy with AHSCT (conditioning regimens
      based on preference of each Centre).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>3 months</time_frame>
    <description>response rate after BeGEV in terms of Complete Response (CR)evaluated by fludeoxyglucose Positron emission tomography (FDG-PET) and Computed Tomography (CT-scan) after four cycles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>3 months</time_frame>
    <description>To assess the response rate after BeGEV in terms of overall response rate (ORR) =Complete Response (CR) plus Partial Response (PR)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mobilization potential of the combination</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate the mobilization potential of BeGEV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity of the combination</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate the toxicity of BeGEV in terms of haematological and extra-haematological side effects according to CTCAE definitions v 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS), Overall Survival (OS).</measure>
    <time_frame>2 years</time_frame>
    <description>Progression free survival and overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>BeGEV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine, Gemcitabine and Vinorelbine (BeGEV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Schedule:
Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles</description>
    <arm_group_label>BeGEV</arm_group_label>
    <other_name>Ribomustin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles</description>
    <arm_group_label>BeGEV</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles</description>
    <arm_group_label>BeGEV</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  relapsed/refractory disease after receiving one line of standard chemotherapy

          -  history of classical Hodgkin's Lymphoma (HL)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

          -  at least one site of measurable nodal disease at baseline ≥ 1.5 cm

          -  Absolute Neutrophils Count (ANC) ≥ 1.5 x 109/L; Platelets count ≥ 75 x 109/L

        Exclusion Criteria:

          -  Diagnosis of Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL)

          -  prior radiation therapy ≤ 3 weeks prior to start of study treatment

          -  any concurrent anti-cancer therapy

          -  evidence of another malignancy not in remission or history of such a malignancy within
             the last 2 years.

          -  aspartate aminotransferase (AST/SGOT) and/or alanine aminotransferase (ALT/SGPT) ≥ 2.5
             x upper limit of normal (ULN) or ≥ 5.0 x ULN if the transaminase elevation is due to
             disease involvement

          -  known history of Human immunodeficiency virus (HIV)seropositivity

          -  hepatitis B virus (HBV) or hepatitis B virus (HCV)active hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armando Santoro, MD</last_name>
    <phone>+39 (0)2 8224</phone>
    <phone_ext>4080</phone_ext>
    <email>armando.santoro@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rita Mazza, MD</last_name>
    <phone>+39 (0)2 8224</phone>
    <phone_ext>4780</phone_ext>
    <email>rita.mazza@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
      <phone>+39 (0)2 8224</phone>
      <phone_ext>4080</phone_ext>
      <email>armando.santoro@humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Rita Mazza, MD</last_name>
      <phone>+39 (0)2 8224</phone>
      <phone_ext>4780</phone_ext>
      <email>rita.mazza@humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Armando Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Mazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Armando Santoro, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Hodgkin</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>refractory</keyword>
  <keyword>relapsed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

